Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL395589 | 1.00 | — | — | |
| SCHEMBL1750165 | 0.86 | — | — | |
| Potassium Ion SCHEMBL640516 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1207561 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| Potassium Ion SCHEMBL8433562 | 0.86 | — | — | |
| SCHEMBL639786 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9641891 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL31511971 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9304336 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| Zinc Ion SCHEMBL917737 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574120-A | Oraglycone Process for the preparation of intermediates | 杭州诺澳生物医药科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-119944063-A | Preparation of organic lithium compound supported activator material and application of organic lithium compound supported activator material in aspect of electrolyte refining | 中国科学院广州能源研究所 | 2025-05-06 | — | — | CN | claimed |
| CN-119608528-A | Preparation method and application of double-layer flexible structure molecular layer deposition coating | 广东原能科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119039494-A | Metal catalyst, catalyst composition and application thereof | 万华化学集团股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118150658-A | Intramolecular anchor chain electrochemical sensor based on tag protein and receptor protein and preparation and application thereof | 华东师范大学 | 2024-06-07 | — | — | CN | claimed |
| WO-2024078387-A1 | SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS, AND USES | 天津谷堆生物医药科技有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-116947731-A | Deuterated aryl pyrrolidone aniline herbicide, and preparation method and application thereof | 河南蓝创作物科学有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. | 2022-06-09 | — | — | US | claimed |
| EP-3953329-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Biogen MA Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114026066-A | Process for preparing alpha-carboxamide pyrrolidine derivatives | 生物基因麻省公司 | 2022-02-08 | — | — | CN | claimed |
| EP-3423457-B1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | claimed |
| WO-2020210485-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN MA INC. (US) | 2020-10-15 | — | — | WO | claimed |
| EP-3423457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | claimed |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | GENENTECH, INC. (US) | 2017-09-07 | — | — | US | claimed |
| EP-0915699-A4 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-06-25 | — | — | EP | claimed |
| US-6080862-A | PREPARING (1S, 2R, 3S)-3-(2-HYDROXYETH-1-YLOXY)-4-METHOXYPHENYL) 1-(3,4-METHYLENEDIOXYPHENYL) 5-(PROP-1-YLOXY)INDANE-2-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-27 | — | — | US | claimed |
| EP-0915699-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-19 | — | — | EP | claimed |
| WO-1997017071-A1 | STEREOSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-15 | — | — | WO | claimed |
| CN-116947840-B | CDK degradation agent and application thereof | 润佳（苏州）医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-0267691-A2 | Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity. | SCHERING CORPORATION (US) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177426-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CPS1, PCCA, ALDH18A1 | ALDH1A1 614/4885 |
| US-20170252457-A1 | PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE | FUCA2, MRPL21, FNTB | ALDH1A1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.